Not-for-profit pledge sees British firm’s sales revenue fall significantly short of US rival Pfizer
AstraZeneca has reported a boost in sales of its Covid-19 vaccine, which tripled to $1.2bn (£900m) in the first half of this year – but remained significantly below the earnings of its US rival Pfizer.
Britain’s biggest drugmaker revealed that it had generated $894m from Covid-19 vaccine sales in the three months to the end of June, following $275m in the first three months of the year. It has pledged to provide the jab, which it developed with Oxford University, on a not-for-profit basis during this pandemic.
